Celldex Therapeutics (CLDX) Gains on CDX-0159 Update, Which Has Drug 'In the Driver's Seat'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Celldex (CLDX) Prices Upsized 5.95M Share Offering at $42/sh
July 14, 2021 5:04 AM EDTCelldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 892,857 shares of common stock at the public offering price, less underwriting discounts and commissions.
Jefferies, SVB Leerink, Guggenheim Securities and Cantor are acting as the joint book-running managers for the offering. LifeSci Capital LLC and H.C. Wainwright & Co. are acting as co-lead... More
Celldex (CLDX) Announces up to $175M Share Offering
July 12, 2021 4:01 PM EDTCelldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $175 million of shares of its common stock in an underwritten public offering. Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares of common stock offered in the public offering. All of the shares of common stock are being offered by the Company. Celldex intends to use the net proceeds from the offering to continue clinical and preclinical development of its product candidates and for... More
Celldex Therapeutics (CLDX) PT Raised to $61 at Cantor Fitzgerald
July 12, 2021 1:22 PM EDTCantor Fitzgerald analyst Kristen Kluska raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $61.00 (from $35.00) while maintaining a Overweight rating.
... MoreCelldex Therapeutics (CLDX) PT Raised to $50 at H.C. Wainwright
July 12, 2021 6:21 AM EDTH.C. Wainwright analyst Joseph Pantginis raised the price target on Celldex Therapeutics (NASDAQ: CLDX) to $50.00 (from $36.00) while maintaining a Buy rating following updated Phase 1b data from the ongoing Phase 1b study of CDX-0159.
The analyst commented, "Celldex reported updated Phase 1b data from the ongoing Phase 1b study of... More
